 Neutrophils play an important role in fighting off viral infections such as COVID-19. However, they can also cause damage to the body when overproducing neutrophil extracellular traps, nets. In this study, researchers found that neutrophils from hospitalized patients with COVID-19 produced significantly more nets than those from healthy individuals. They also discovered that a protein kinase C, PKC, inhibitor called Ruboxystaurin reduced net production and associated tissue damage. This suggests that Ruboxystaurin may be a potential treatment option for reducing the harmful effects of nets caused by COVID-19. This article was authored by Rebecca Dowey, Joby Cole, A.A. Roger Thompson, and others.